Efficacy and safety of micronised fenofibrate in a randomised double-blindstudy comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia
M. Krempf et al., Efficacy and safety of micronised fenofibrate in a randomised double-blindstudy comparing four doses from 200 mg to 400 mg daily with placebo in patients with hypercholesterolemia, DIABETE MET, 26(3), 2000, pp. 184-191
The aim of this study was to evaluate the efficacy on LDL-cholesterol (LD L
-C) of micronised fenofibrate given for three months at doses ranging from
200 to 400 mg once daily, compared with placebo. A double-blind, randomised
, parallel-group, multi-centre trial was performed in four centers of Franc
e in 340 hypercholesterolemic patients (163M, 177F) aged 18-75 years. After
a 2-3 month single-blind run-in period on placebo and diet, patients with
LDL-C greater than or equal to 4.65 mmol/l (180 mg/dl) maintained on the sa
me diet throughout the study were randomly allocated to placebo or to 200,
267, 340 or 400 mg micronised fenofibrate, given once daily with the evenin
g meal for 3 months. LDL-C, total cholesterol (TC), total triglycerides (TG
) and apolipoprotein B (Apo B) significantly decreased compared with placeb
o in all four fenofibrate groups. For all randomised patients, the decrease
in the fenofibrate groups ranged from 31.6-38.8% for LDL-C, 24.5-31.9% for
TC, 26.7-40.8% for TG, and 27.3-35.0% for Apo B. An increase in HDL-choles
terol of 4.1-8.2% was observed in the fenofibrate groups, but did not reach
statistical significance. Lipid values in the placebo group remained uncha
nged. The therapeutic goal of LDL-C < 3.36 mmol/l (130 mg/dl)was reached in
27% in the 200 mg group and increased to 56% in the 300 mg group.
There were no major clinical or biological adverse events in the dose inter
val from 200 mg to 400 mg of micronised fenofibrate per day. This study sho
wed treatment for 3 months with micronised fenofibrate at doses up to 400 m
g per day is effective and can reduce LDL-cholesterol up to 30% allowing fu
rther evaluation of these doses on longer trials.